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Background/aim: Carbapenem-resistant Klebsiella pneumoniae (CR-KP) infections encountered in urology patients differentiate from
infections caused by other factors, both in respect to prophylaxis and treatment stage, and require a special approach. We aimed to
analyse the predisposing factors and the antibiotherapies for CR-KP infection outbreak in a tertiary urology clinic.
Materials and methods: There were 75 patients in the CR-KP positive group (Group I) and 146 patients in the CR-KP negative group
(Group II). Analysis of the predisposing factors for CR-KP infection and comparison of the reinfection rate and the antibiotherapies in
the 2 groups were the endpoints.
Results: In the first group, age, comorbidity, previous antibiotic use, and nephrostomy tube rates were higher (P = 0.015, P = 0.001, P
= 0.004, and P < 0.001, respectively). In the second group, open urological surgery rate, and the proportion of patients presenting with
flank pain, lower urinary tract symptoms, and haematuria were higher (P = 0.029, P < 0.001, P < 0.001, and P = 0.007). In the first group,
the proportion of patients treated with transurethral bladder tumour resection was higher, whereas, percutaneous nephrolithotomy
was higher in the second group (P = 0.045 for both). While hospitalization and Foley catheterization duration were longer in the first
group (P < 0.001 for both), double J stent and nephrostomy duration were longer in the second group (P < 0.001 and P = 0.005). Mean
leukocyte count at admission was higher in the first group (P < 0.001).
Conclusion: Advanced age, comorbidities, previous antibiotic use, and prolonged Foley catheterization duration are predisposing factors
for this infection in the urology department. Two-week administration of combination antibiotic regimens containing carbapenem were
effective for the treatment of this infection.
Key words: carbapenem-resistant Klebsiella pneumonia, antibiotic resistance, urological infection, urological surgery

1. Introduction
World-wide increased antibiotic resistance is a global
threat to the health system. Recently, carbapenem-resistant
gram-negative bacteria have become quite another
multiresistant infectious agent with limited treatment
options. Carbapenem-resistant Klebsiella pneumonia (CRKP) hydrolyses carbapenems via β-lactamase enzyme
and thus shows resistance to many antimicrobial agents
[1,2]. Unfortunately, these organisms also have resistance
mechanisms for the second line antibiotics. In some
recent studies, it has been demonstrated that they may
also show resistance to the last option antibiotics such as
tigecycline and colistin [3–5]. The importance of antibiotic
stewardship in the management of patients has been
highlighted and practical guidelines have been developed

for the benefit of clinicians for the treatment of urinary
tract infections (UTIs) [6,7].
Patients hospitalized in the urology clinic are
estimated to have a hospital-related global infection rate of
10%–12% [8]. UTI is the most common type of infection
in urology practice, with an annual global case number
of approximately 150–250 million [9]. UTIs are a major
cause of antibiotic use and resistance due to their high
prevalence [10]. However, risks associated with urological
procedures can be reduced by appropriate and effective
antibiotic regimens.
Patients hospitalized in the urology clinic have a higher
rate of urinary catheterization than other clinics and most
of these patients undergo urological surgery. On the
other hand, urinary catheterization and surgery are well-
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known risk factors for infection [11]. CR-KP infections
encountered in urology patients differentiate from
infections caused by other factors, both in prophylaxis
and treatment stage, and require a special approach. UTIs
caused by CR-KPs are often poor prognostic and difficult
to treat [12,13].
In the literature, numerous review and meta-analysis
are available related to trends in urological infection
resistance, their effect on the urological procedures and
in regard to antibiotics used. In this controlled trial, we
aimed to analyse the factors in the emergence of CR-KP
infections in a high-volume urology clinic.
2. Materials and methods
2.1. Patient selection and data collection
Between June 2016 and January 2019, 81 patients who
were treated in our clinic and had a CR-KP in urine culture
and 151 patients without CR-KP were the subjects of this
study. All patients with CR-KP infection, in that period,
were included in the study. The control group consisted
of patients who were treated for different reasons in our
clinic and had no CR-KP infection in the same period.
Six patients whose data were not able to reach in the CRKP group and 5 patients in the non-CR-KP group were
excluded from the study, and the remaining 221 patients
were included in the study. The study flowchart is shown
in Figure 1.
Demographic data of the patients, operations, duration
of hospitalization, presence of a Foley catheter, double J
stent and nephrostomy tube, duration of catheterization,
complaints at admission, isolated agents in a urine culture,
duration of treatment, the antibiotherapies, reinfection
rate and treatment of reinfection and isolated agents
were recorded from patient files. The data were compared
between the 2 groups and the factors that make a significant
difference in the development of CR-KP infection among
the 2 groups were evaluated. All phases of the study were
carried out in accordance with the Declaration of Helsinki
or its subsequent amendments. The study protocol was
approved by the hospital ethics committee (decision
number: 19-5.2T/40 and decision date: 29.05.2019). All
patients participating in the study gave written approval
for the procedures to be performed.
2.2. Microbiological methods
The minimum inhibitory concentration (MIC) is the
lowest antibiotic concentration that inhibits the growth
of a particular microorganism for a specific antibiotic.
Antimicrobial sensitivity to meropenem and ertapenem
is described as follows; resistant, MIC ≥ 16 mg/mL and
MIC ≥ 8 mg/L, respectively (for Klebsiella). Sensitivity was
defined for colistin, as susceptible, MIC ≤ 0.5 mg/mL (for
Klebsiella).
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Figure 1. Study flow-chart.

2.3. Outcome measures
The primary endpoint of the study was the comparison of
predisposing factors between the 2 groups leading to CRKP infection. The secondary endpoint was a comparison
of the reinfection rate and the antibiotherapies in the 2
groups.
2.4. Statistical analysis
The means of 2 groups were compared with independent
samples t-test. The chi-square tests were used for testing
relationships between categorical variables. The pearson
chi-square statistic was used in the test of independence.
The Mann–Whitney U test is used to compare differences
between 2 independent groups when the dependent
variable is either ordinal or continuous, but not normally
distributed. Logistic regression analysis was performed
for variables that were significant in univariate analysis
and predictive factors for CR-KP infection development
were evaluated. P values that were considered significant
in univariate and multivariate analysis were 0.05 and 0.2,
respectively. All statistical analysis was performed with the
SPSS statistical software program version 22.0 (IBM Corp.,
Armonk, NY, USA).
3. Results
Data of 221 patients were analysed. CR-KP infection was
positive in 75 patients, while 146 patients were in the CRKP negative group. In Group I, the comorbidity rate was
higher than Group II (40.0% vs 16.4%, P = 0.001). No
significant difference was observed between the 2 groups
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in terms of proportion of endourologic operations, while
the proportion of open operations was higher in Group
II (17.3% vs. 32.9%, P = 0.029). Antibiotic use prior to
hospitalization was significantly higher in the first group
(37.3% vs 16.4%, P = 0.004). There was no significant
difference between 2 groups in terms of urological diseases
(P > 0.05). In the first group, the rate of private toilet in
the hospital room was higher (21.3% vs. 6.8%, P = 0.012).
While no significant difference was observed in terms of
Foley catheter and double J stent rate, the nephrostomy
tube rate was higher in the first group (34.7% vs 4.1%, P
< 0.001). Complaints associated with flank pain, lower

urinary tract symptoms and haematuria were higher in the
second group (2.7% vs 28.8%, P < 0.001; 4.0% vs 27.4%, P <
0.001; 4.0% vs 17.8%, P = 0.007, respectively). Comparison
of demographic data, comorbidities and presentation
complaints among the groups is summarized in Table 1.
In the first group, the proportion of patients underwent
transurethral bladder tumour resection was significantly
higher (27% vs 13.7%, P = 0.045), while the proportion
of patients underwent percutaneous nephrolithotomy was
higher in the second group (2.7% vs 11%, P = 0.045). The
comparison of the groups according to the implemented
operations is given in Table 2.

Table 1. Comparison of demographic data, comorbidities and complaints at admission of the CRE
positive and negative patients.
Variables

Group I
(n = 75)

Group II
(n = 146)

P-value

Age

64.7 ± 13.2

58.8 ± 15.5

0.015

Comorbidity

30 (40)

24 (16.4)

0.001

Diabetes mellitus

8 (10.7)

10 (6.8)

0.412

Operation history

34 (45.3)

72 (49.3)

0.628

Open urological surgery history

13 (17.3)

48 (32.9)

0.029

Antibiotic use

28 (37.3)

24 (16.4)

0.004

Bladder tumour

28 (37.3)

44 (30.1)

0.355

Kidney tumour

5 (6.7)

16 (11)

0.356

Benign prostatic hyperplasia

7 (9.3)

8 (5.5)

0.372

Prostate cancer

15 (20)

18 (12.3)

0.206

Ureteral stone

7 (9.3)

18 (12.3)

0.557

Kidney stone

5 (6.7)

16 (11)

0.356

Urethral stricture

10 (13.3)

18 (12.3)

0.855

Fournier gangrene

2 (2.7)

4 (2.7)

0.978

Hydronephrosis

13 (17.3)

26 (17.8)

0.970

Private toilet in the hospital room

16 (21.3)

10 (6.8)

0.012

Foley catheter

65 (86.7)

130 (89)

0.659

Double J stent

28 (37.3)

38 (26)

0.140

Nephrostomy tube

26 (34.7)

6 (4.1)

<0.001

Flank pain

2 (2.7)

42 (28.8)

<0.001

Lower urinary tract symptoms

3 (4)

40 (27.4)

<0.001

Haematuria

3 (4)

26 (17.8)

0.007

Urological diseases

Urological catheter

Complaints at admission

Values are given as mean ± standard deviation or number (%)
Group I: Carbapenem resistant enterobacteriaceae positive patients; Group II: Carbapenem
resistant enterobacteriaceae negative patients.
Significant P values are given in bold and italics.
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There was a significant difference between the 2 groups
in terms of hospitalization, Foley catheter, double J stent, and
nephrostomy duration (P < 0.001, P < 0.001, P < 0.001, and
P = 0.005, respectively). While the mean leukocyte count
was significantly higher in the first group (P < 0.001), there
was no significant difference between the 2 groups in terms
of mean C-reactive protein (CRP) value at admission (P =
0.288). Foley catheter duration was longer in the first group,
while the double J stent and nephrostomy tube durations
were longer in the second group. The comparison of
hospitalization and catheter durations and mean leukocyte
and CRP values are shown in Table 3 and Figure 2.

In the CR-KP negative group, urine culture was positive
in 18 patients (12.3%) and 4 of them were Klebsiella
pneumonia (2.7%). In this group, 140 patients received
treatment (95.9%). Antibiotics used in the second group
are shown in Figure 3. The most frequently used antibiotic
periods were 1-day (20.9%) and 5-day (7.4%) intervals,
respectively. None of the patients in this group had a fever
of more than 38 °C and reinfection.
In the CR-KP positive group, 8 patients presented with
fever (10.7%) and 3 patients with sepsis (4%). The urine
culture of 74 patients was positive and the isolated agents
were CR-KPs in all of them. Treatment was initiated on

Table 2. The comparison of the groups according to the operations.
Group I
(n = 75)

Group II
(n = 146)

P-value

Transurethral bladder tumour resection

20 (27)

20 (13.7)

0.045

Ureterorenoscopy

8 (10.7)

16 (11)

0.954

Endoscopic internal urethrotomy

9 (12)

28 (19.2)

0.228

Percutaneous nephrolithotomy

2 (2.7)

16 (11)

0.045

Double J stent implementation

13 (17.3)

20 (13.7)

0.542

Fournier’s gangrene debridement

3 (4)

4 (2.7)

0.671

Radical cystectomy + urinary diversion

6 (8)

4 (2.7)

0.157

Radical nephrectomy

2 (2.7)

10 (6.8)

0.231

Partial nephrectomy

2 (2.7)

6 (4.1)

0.627

Retropubic radical prostatectomy

8 (10.7)

8 (5.5)

0.248

Operation
Endoscopic operations

Open operations

Values are given as number (%)
Group I: Carbapenem resistant enterobacteriaceae positive patients; Group II: Carbapenem
resistant enterobacteriaceae negative patients.
Significant P values are given in bold and italics.
Table 3. The comparison of hospitalization and catheter durations and leukocyte and CRP values.
Variables

Group I
(n = 75)

Group II
(n = 146)

P-value

Hospitalization duration

8.83 ± 9.24

3.40 ± 3.86

<0.001

Foley catheter duration

7.62 ± 7.70

3.45 ± 4.23

<0.001

Double J stent duration

28.14 ± 74.31

91.11 ± 123.24

<0.001

Nephrostomy duration

36.51 ± 93.78

253.33 ± 193.41

0.005

Leukocyte count at admission

10,931.49 ± 5061.90

8211.13 ± 3602.82

<0.001

C-reactive protein at admission

9.67 ± 8.64

5.23 ± 4.84

0.288

Values are given as mean ± standard deviation.
Group I: Carbapenem resistant enterobacteriaceae positive patients; Group II: Carbapenem resistant
enterobacteriaceae negative patients.
Significant P values are given in bold and italics.
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80% of the patients (n = 60) and antibiotherapies are
summarized in Figure 4. The most common preferred
treatments were Meropenem + Daptomycin (26.9%)
and Meropenem + Ertepenem (25.2%) combinations.
The most common treatment period was 14-day interval
in 18.9% of the patients. Reinfection was seen in 20 of
these patients (26.7%). In all, the isolated agent in the
urine culture was Klebsiella pneumonia. Five (25%) had
a fever of more than 38 °C. Sixteen (80%) had urological
intervention before reinfection and 11 of them were open
surgeries (68.7%). Meropenem was used in 49 patients
(65.3%) and all of them were drug-resistant (MIC ≥ 16

mg/mL). Ertapenem was used in 35 patients (46.7%) and
all of 35 were drug-resistant (MIC ≥ 8 mg/mL). Colistin
was used in 14 patients (16.9%) and all were susceptible to
the drug (MIC ≤ 0.5 mg/mL).
In the multivariate analysis, age, comorbidity, private
toilet in the hospital room, Foley catheter duration,
presence of nephrostomy, and complaints on admission
were significantly different between the 2 groups.
Multivariate analysis of predisposing factors for CR-KP
infection is shown in the Table 4.
The most common interval from the urological surgery
to CR-KP positivity was a 60-day interval, in 17.9% of the

Figure 2. The comparison of hospitalization, foley catheter, double j stent, and nephrostomy
tube durations.

Figure 3. Antibiotics used in CRE negative group.
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Figure 4. Antibiotics used in CRE positive group.
Table 4. Multivariate analysis of predisposing factors for CRE infection.

Variables

95% C.I. for EXP(B)
Sig.

Exp(B)

Lower

Upper

Age (years)

0.018

1.029

1.005

1.054

Comorbidity

0.002

3.389

1.565

7.336

Diabetes mellitus

0.416

1.624

0.505

5.217

Endourologic operation history

0.543

1.321

0.539

3.236

Urethral stricture

0.855

1.094

0.417

2.870

Fournier gangrene

0.978

0.973

0.133

7.094

Hydronephrosis

0.970

0.984

0.422

2.295

Fournier gangrene debridement

0.673

1.479

0.240

9.120

Radical cystectomy + urinary diversion

0.176

3.087

0.602

15.822

Private toilet in the hospital room

0.016

3.688

1.274

10.677

Foley catheter

0.659

0.800

0.297

2.156

Foley catheter duration

0.002

1.118

1.043

1.199

Double J stent

0.623

1.215

0.559

2.639

Double J stent duration

0.737

1.001

0.996

1.005

Nephrostomy

<0.001

12.381

3.549

43.197

Nephrostomy duration

0.072

1.005

1.000

1.011

Complaints at admission

<0.001

10.500

4.908

22.462

Significant P values are given in bold and italics.

patients, and the second most common interval was 30day, in 11.9% of the patients. On the other hand, the most
common interval from hospitalization to CR-KP positivity
was 60-day, in 18.7% of the patients, and secondly 30-day
in 10.7% of the patients.
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4. Discussion
Carbapenem resistance in Enterobacteria, which is mainly
associated with the mechanisms associated with plasmidencoded carbapenemases, is an increasing and important
global health problem [14–16]. Excessive consumption
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of carbapenems used to treat extended spectrum betalactamase (ESBL) gram-negative infections has led to
increased carbapenem resistance, particularly for E.coli
and Klebsiella, which are responsible for the majority of
urological infections. However, the significant cost of
treatment, prolonged hospitalization and loss of the labour
force have emerged.
Patients with indwelling catheters constitute major
reservoirs for multi-resistant bacteria. The catheterassociated UTI may be formed by the extraluminal route
through the bacteria entering the bladder from the biofilm
formed around the catheter in the urethra or intraluminal
route by the urinary stasis caused by drainage failure or
ascending infection with contamination of the urine
collection reservoir [17]. It is known that the duration
of catheterization is the most important risk factor for
bacteriuria [18]. In patients with indwelling catheter,
bacteriuria occurs at a rate of 3%–10% per day of catheter
[19]. In our study, we found that patients with Foley catheter
and nephrostomy tube had more CR-KP infections and
the duration of catheterization was significantly extended
in these patients. We could not show a similar effect for
the double J stent. Long-term Foley catheterization and
nephrostomy tube may be an important risk factor for
CR-KP infections by extraluminal route and minimizing
the duration of Foley catheter and nephrostomy in these
patients may be an effective method to prevent these
infections.
High urolithiasis incidence, lower urinary tract
symptoms and history of urinary infection, and prolonged
use of antibiotics as a result of these are considered as
the responsible factors for the development of antibiotic
resistance in urological patients [20]. In addition, a
patient in the urology clinic has a possibility of having a
urological operation of approximately 75%, of which 55%
are endourological operations [21]. In non-urological
clinics, urinary infections constitute 15%–57% of hospitalacquired infections, while this rate is 70% in urology clinics
[21,22]. In our study, there was no significant difference in
the prevalence of renal and ureteral stones between the 2
groups. Since our country is located in an endemic region
for stone disease and our clinic is a reference centre for
stone patients in the region, a large number of stone patients
are being treated. Therefore, no significant difference
might be observed between the 2 groups. The history of
antibiotic use, which is a reflection of previous infections,
was found to be higher in the first group, a possible cause
of carbapenem resistance. There was also a significant
difference between the 2 groups in terms of the operation
type, as follows: in the first group, the prevalence of open
operation was lower and the prevalence of transurethral
bladder tumour resection which is an endourologic
operation was higher. Shorter Foley catheter duration in
open operations and longer catheterization duration due

to resection of large and necrotic bladder tumours and
recurrent haematuria attacks may be responsible from this
difference.
Age and comorbidities such as immunosuppression,
diabetes, obesity, liver dysfunction and malnutrition are
well known risk factors for hospital-acquired infections
[23]. In our study, we found that the first group consisted
of older and more comorbid patients in accordance with
this data.
In areas with high antibiotic resistance, antibiotics
such as fosfomycin, nitrofurantoin, tigecycline, colistin,
and carbapenem are recommended for the treatment
of UTIs rather than fluoroquinolone [24]. Since colistin
is nephrotoxic, and it should not be used alone in this
infection, because of increasing resistance. The MIC values
of microorganisms guide the selection of antibiotics, and
preferably the combination with a carbapenem group
antibiotic is beneficial. In general, the combination therapy
with a carbapenem group antibiotic has been shown
to provide a synergistic effect in the treatment of these
resistant infections [25,26]. The rationale of combination
of 2 or more agents is the reduction in the mortality
rate caused by severe CR-KP infections, resistance may
occur during monotherapy, and insufficient evidence of
the effectiveness of monotherapy. In many observational
studies, it has been shown that combination therapy can
reduce mortality rates [27,28]. Therefore, although resistant
to all, we preferred antibiotic combinations of carbapenem
group containing meropenem and ertapenem in 65% and
46% of our patients, respectively. In a retrospective study
of 230 patients, ertapenem was shown to be effective in the
treatment of complicated UTIs caused by ESBL-producing
microorganisms, and in particular, patients undergoing
urinary catheterization, urologic intervention and those
with diabetes were under risk for superinfection [29]. If
the isolate is susceptible, polymyxin-based combination
regimens may also be beneficial. In our study, colistin,
which was used in approximately one-fifth of patients,
was susceptible for all isolates with very low MIC values.
However, the transition of tigecycline to urine is 1%, it
may also be considered among the second-line treatment
agents. Plazomicin is a promising new aminoglycoside
antibiotic in the treatment of carbapenemase producing
isolates resistant to old aminoglycosides [30]. In our
study, dual combination therapies were the most
preferred treatment protocols for CR-KP infections and
14-day antibiotherapy interval was the most commonly
used treatment protocol. The reason for the high rate of
reinfection may be the rehospitalization of these patients
due to recurrent endourologic interventions such as
control cystoscopy and ureteroscopy.
Empirical treatment can be introduced without any
urine culture with a carefully taken clinical history for
the treatment of UTIs. However, in some areas with
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high antibiotic resistance or in cases where symptoms
are uncertain, the infectious agent should be identified
with microbiological analysis. In our study, we found
that the group with negative CR-KP infection was
more symptomatic (flank pain and lower urinary tract
symptoms) than the positive group.
Our study has some limitations. Our retrospective
study included a short period of time when CR-KP
infections peaked. Secondly, this study, which reflects the
results of a single-centre, has a relatively limited number
of patients.
In conclusion, CR-KP infection is an increasing
problem and necessary precautions should be taken in
the urology clinics for prevention and prophylaxis and
treatment should be administered with appropriate
agents. In particular, advanced age, comorbidities,
previous antibiotic use, transurethral resection, longterm Foley catheterization are important risk factors for
these infections. Notably, the two-week combination of
glycopeptide and lipopeptide antibiotics with carbapenem
group antibiotics appears to be an effective treatment
method for CR-KP infections. The etiopathogenesis of CRKP infections in urology patients may be better clarified

in controlled-prospective studies conducted with large
patient groups.
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